Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Indapamide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 10/20 | 0.73 |
| ▸ | CA1 | P00915 | 9/20 | 0.73 |
| ▸ | CA12 | O43570 | 7/20 | 0.73 |
| ▸ | CA9 | Q16790 | 6/20 | 0.73 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.73 |
| ▸ | CA7 | P43166 | 4/20 | 0.73 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.73 |
| ▸ | CA3 | P07451 | 3/20 | 0.73 |
| ▸ | CA4 | P22748 | 3/20 | 0.73 |
| ▸ | CA6 | P23280 | 3/20 | 0.73 |
| ▸ | CA5A | P35218 | 3/20 | 0.73 |
| ▸ | CA13 | Q8N1Q1 | 3/20 | 0.73 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.73 |
| ▸ | CA5B | Q9Y2D0 | 3/20 | 0.73 |
| ▸ | GAA | P10253 | 1/20 | 0.73 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.73 |
| ▸ | LMNA | P02545 | 4/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.52 |
| ▸ | THRB | P10828 | 1/20 | 0.52 |
| ▸ | APEX1 | P27695 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Indapamide SCHEMBL28248032 | 0.88 | CA2 (0.56) | CA2CA1CA12CA9ALDH1A1 | |
| Indapamide SCHEMBL21630209 | 0.85 | CA1 (0.69) | CA2CA1CA12CA9ALDH1A1 | |
| Indapamide SCHEMBL29372690 | 0.85 | CA1 (1.00) | CA2CA1CA12CA9ALDH1A1 | |
| Indapamide SCHEMBL41303 | 0.85 | CA1 (1.00) | CA2CA1CA12CA9ALDH1A1 | |
| Indapamide SCHEMBL2329030 | 0.85 | CA1 (1.00) | CA2CA1CA12CA9ALDH1A1 | |
| Indapamide SCHEMBL476213 | 0.85 | CA1 (1.00) | CA2CA1CA12CA9ALDH1A1 | |
| Indapamide SCHEMBL29496872 | 0.85 | CA1 (1.00) | CA2CA1CA12CA9ALDH1A1 | |
| Indapamide SCHEMBL163266 | 0.85 | CA1 (1.00) | CA2CA1CA12CA9ALDH1A1 | |
| Indapamide SCHEMBL29377544 | 0.85 | CA1 (1.00) | CA2CA1CA12CA9ALDH1A1 | |
| Indapamide SCHEMBL2989867 | 0.84 | CA1 (0.98) | CA2CA1CA12CA9ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3010890-B1 | BIOORTHOGONAL METHODS AND COMPOUNDS | UNIV COURT UNIV OF EDINBURGH (GB) | 2019-01-02 | — | — | EP | disclosed |
| US-20180362473-A1 | BIOORTHOGONAL METHODS AND COMPOUNDS | UNIV COURT UNIV OF EDINBURGH (GB) | 2018-12-20 | — | — | US | disclosed |
| CN-107405343-A | SALTS AND COMPOSITIONS USEFUL FOR TREATING DISEASE | 明尼苏达大学董事会 | 2017-11-28 | — | — | CN | disclosed |
| US-20160152573-A1 | BIOORTHOGONAL METHODS AND COMPOUNDS | THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH (GB) | 2016-06-02 | — | — | US | disclosed |
| EP-3010890-A1 | BIOORTHOGONAL METHODS AND COMPOUNDS | The University Court of the University of Edinburgh (GB) | 2016-04-27 | — | — | EP | disclosed |
| WO-2014202994-A1 | BIOORTHOGONAL METHODS AND COMPOUNDS | THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH (GB) | 2014-12-24 | — | — | WO | disclosed |
| US-20130053372-A1 | 5-HT RECEPTOR MODULATORS | CAMBRIDGE ENTERPRISE LIMITED | 2013-02-28 | — | — | US | disclosed |
| EP-2536711-A1 | 5-HT RECEPTOR MODULATORS | Cambridge Enterprise Limited (GB) | 2012-12-26 | — | — | EP | disclosed |
| WO-2011098776-A1 | 5-HT RECEPTOR MODULATORS | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2011-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130053372-A1 | 5-HT RECEPTOR MODULATORS | HTR1B, HTR5A, HTR1A | CA2 4146/4885CA1 4456/4885CA12 4794/4885 |
| US-20180362473-A1 | BIOORTHOGONAL METHODS AND COMPOUNDS | DDT, DPYD, DNPEP | CA2 2835/4885CA1 1469/4885CA12 1765/4885 |
| US-20160152573-A1 | BIOORTHOGONAL METHODS AND COMPOUNDS | DDT, DPYD, DNPEP | CA2 2835/4885CA1 1469/4885CA12 1765/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.